Regeneus appoints Japan-based non-executive director
Regeneus appoints Japan-based non-executive director
Sydney, Dec 11, 2017 AEST (ABN Newswire) - Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce the appointment of Leo Lee as an independent non-executive director of Regeneus with effect from December.

Leo is a senior executive with over 20 years of experience in pharmaceutical innovation, commercialization, regulation and policy development. He has worked in North America and Asia and has spent the last 12 years living and working in Japan. Leo is President of Merck Serono, Japan and was previously the President of Allergan, Japan.

Regeneus Chairman, Dr Roger Aston said: "On behalf of the Directors, I welcome Leo to the Regeneus Board. Leo brings a wealth of pharmaceutical business experience gained from his senior leadership roles in Allergan and Merck Serono. His skills, experience, network and knowledge of the Japanese market make him a valuable and strategic addition to the Board particularly with our recent collaboration with AGC in Japan and our focus on clinical licensing and development of Progenza for the Japanese regenerative medicine market".


About Regeneus Ltd

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.

      


Contact

Sandra McIntosh
Company Secretary and Investor Relations
T: +61-2-9499-8010
E: investors@regeneus.com.au
W: www.regeneus.com.au



Related Companies

Regeneus Ltd      

ABN Newswire This Page Viewed:  (Last 7 Days: 31) (Last 30 Days: 133) (Since Published: 2243) 
ANALYTICS: LOGIN HERE

Regeneus Ltd NEWS: RECENT VISITS (4831)

Research Report

Social Media